All In Biotech

Drug Trial Radar · NCT06602193

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

Mar 2027

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Denali Therapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Biogen
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.

Conditions

  • Parkinson Disease

Interventions

  • BIIB122 225 mgDrug

    Administered as specified in the treatment arm

  • BIIB122-Matching PlaceboOther

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) with BIIB122 compared with placebo over the 12-week double-blind periodTime frame: 12 weeks

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Department of Neurology

    Los Angeles, California

  • University of California San Francisco

    San Francisco, California

  • Parkinson's Disease and Movement Disorders Center

    Boca Raton, Florida

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center

    New York, New York

  • Evergreen Health Laboratory

    Kirkland, Washington

  • Inland Northwest Research

    Spokane, Washington

  • Technische Universität Dresden

    Dresden, Germany

  • University of Lübeck

    Lübeck, Germany

  • University Hospital Tübingen

    Tübingen, Germany

  • Rabin Medical Center

    Petah Tikva, Israel

  • Movement Disorders Institute, Sheba Medical Center

    Ramat Gan, Israel

  • Tel Aviv Medical Center

    Tel Aviv, Israel

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitari General de Catalunya

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Spain

  • Universitary Hospital La Princesa

    Madrid, Spain

  • IDIVAL/University Hospital Marques de Valdecilla

    Santander, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.